GAMMA Investing LLC Has $78,000 Position in MorphoSys AG (NASDAQ:MOR)

GAMMA Investing LLC boosted its stake in shares of MorphoSys AG (NASDAQ:MOR) by 42.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,092 shares of the company’s stock after buying an additional 1,218 shares during the quarter. GAMMA Investing LLC’s holdings in MorphoSys were worth $78,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rhumbline Advisers lifted its stake in shares of MorphoSys by 17.8% in the 2nd quarter. Rhumbline Advisers now owns 5,187 shares of the company’s stock valued at $94,000 after purchasing an additional 785 shares during the period. Virtu Financial LLC acquired a new position in shares of MorphoSys in the 4th quarter valued at about $244,000. SAL Trading LLC acquired a new position in shares of MorphoSys in the 1st quarter valued at about $486,000. BNP Paribas Financial Markets increased its position in MorphoSys by 130.4% in the 1st quarter. BNP Paribas Financial Markets now owns 32,533 shares of the company’s stock valued at $590,000 after buying an additional 18,413 shares in the last quarter. Finally, Susquehanna International Group Ltd. bought a new stake in MorphoSys in the 1st quarter valued at about $1,333,000. 18.38% of the stock is owned by institutional investors and hedge funds.

MorphoSys Stock Performance

Shares of MorphoSys stock opened at $18.96 on Wednesday. MorphoSys AG has a one year low of $4.18 and a one year high of $19.50. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of -5.45 and a beta of 1.20. The business has a 50-day simple moving average of $18.96 and a 200 day simple moving average of $18.52. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.38 and a quick ratio of 1.38.

MorphoSys Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.